SKYE vs VLTO · $25.0M cap vs P/E 29, rev $5.50B
Skye Bioscience, Inc. Common Stock (SKYE) versus Veralto Corporation (VLTO) — a side-by-side from cached financials, not a winner call.
Skye Bioscience, Inc. Common Stock (SKYE) is a biotechnology company listed on NASDAQ.
Veralto Corporation (VLTO) is a pollution & treatment controls company listed on US.
SKYE does not have a complete income-statement cache yet.
Latest reported VLTO revenue for 2025-12-31 was $5.50B. Net income was $940.0M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
SKYE currently screens at market cap $25.0M. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
Not investment advice. Open the SKYE and VLTO stock pages for the full models.
Not investment advice.